Investigating the effect of actinomycin D and methotrexate on ovarian reserve in patients with trophoblastic tumor of low risk pregnancy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240514061800N5

Enrollment

Registered

2024-10-09

Start date

2024-10-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-risk gestational trophoblastic tumor. Complete hydatidiform mole

Interventions

Intervention 1: Intervention group: In this group, patients receive actinomycin D (Merck Elman) intravenously at a dose (1.25 mg/m2) once every two weeks. Intervention 2: Intervention group: In this g

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Positive history of amenorrhea or irregular menstruation Cystic changes Chorionic villi myometrium

Exclusion criteria

Exclusion criteria: The presence of any endocrine disorder History of previous surgery on the ovaries Hypothyroidism hyperthyroidism Cushing syndrome

Design outcomes

Primary

Measure	Time frame
Anti Mullerian Hormone. Timepoint: Before and after treatment. Method of measurement: Laboratory method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSetareh Nasiri Zeidi

Iran University of Medical Sciences

sogand.hd74@gmail.com+98 21 5560 6034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026